Abstract
The demand for blood products containing factor VIII for treating patients with haemophilia A in south-east Scotland was reviewed. From 1961 to 1975 the demand for fresh frozen plasma (FFP), cryoprecipitate (CP), and antihaemophilic factor (AHF) increased by seven and a half times, while total donations increased by only a third. Patients with severe haemophilia A treated at the regional haemophilia centre used about 85% of the factor VIII issued in 1971-4, most of which was used on demand. A patient with severe haemophilia A on unlimited ondemand home treatment would need about 500 units of factor VII/kg body weight/year, and a regional haemophilia centre, treating moderate and mild cases as well as severe ones, would use 15000 units/patient/year. Altogether about 50 million units of factor VIII will be needed each year in the UK. Although cryoprecipitate is much harder to store and administer than AHF, its yield from plasma may be far greater and its cost far smaller. Unless the blood transfusion services receive increased amounts of money and reappraise their functions and operation, it seems likely that they will have to rely increasingly on commercial (and costly) sources for the major plasma fractions.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bloom A. L., Giddings J. C., Bevan B., Letton M., Drummond R. J. Comparison of qucik and slow thaw methods of producing cryoprecipitate antihaemophilic factor from fresh and 24-hour-old blood. J Clin Pathol. 1969 Jul;22(4):447–452. doi: 10.1136/jcp.22.4.447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Burka E. R., Puffer T. M., Holburn R. R., Sherwood W. C. The unsuitability of outdated blood for making therapeutically effective cryoprecipitate. Transfusion. 1973 Nov-Dec;13(6):412–417. doi: 10.1111/j.1537-2995.1973.tb04469.x. [DOI] [PubMed] [Google Scholar]
- Buxton M. J., West R. R. Cost-benefit analysis of long-term haemodialysis for chronic renal failure. Br Med J. 1975 May 17;2(5967):376–379. doi: 10.1136/bmj.2.5967.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Carter F., Macfarlane J., Forbes C. D., Prentice C. R., Wallace J. Costing cryoprecipitate for haemophilia. Br Med J. 1975 May 3;2(5965):256–256. doi: 10.1136/bmj.2.5965.256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lazerson J. Hemophilia home transfusion program: effect of cryoprecipitate utilization. J Pediatr. 1973 May;82(5):857–859. doi: 10.1016/s0022-3476(73)80083-6. [DOI] [PubMed] [Google Scholar]
- Le Quesne B., Britten M. I., Maragaki C., Dormandy K. M. Home treatment for patients with haemophilia. Lancet. 1974 Aug 31;2(7879):507–509. doi: 10.1016/s0140-6736(74)92029-7. [DOI] [PubMed] [Google Scholar]
- Levine P. H., Britten A. F. Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Ann Intern Med. 1973 Feb;78(2):195–201. doi: 10.7326/0003-4819-78-2-195. [DOI] [PubMed] [Google Scholar]
- Newman J., Johnson A. J., Karpatkin M. H., Puszkin S. Methods for the production of clinically effective intermediate- and high-purity factor-VIII concentrates. Br J Haematol. 1971 Jul;21(1):1–20. doi: 10.1111/j.1365-2141.1971.tb03413.x. [DOI] [PubMed] [Google Scholar]
- Rabiner S. F., Telfer M. C. Home transfusion for patients with hemophilia A. N Engl J Med. 1970 Nov 5;283(19):1011–1015. doi: 10.1056/NEJM197011052831902. [DOI] [PubMed] [Google Scholar]
- Shanberge J. N., Gruhl M. C., Ikemori R., Inoshita K., Chalos M. K., Aster R. H. A comparison of factor VIII activity in cryoprecipitates prepared from ACD and CPD plasma. Transfusion. 1972 Jul-Aug;12(4):251–258. doi: 10.1111/j.1537-2995.1972.tb00043.x. [DOI] [PubMed] [Google Scholar]
- Verstraete M., Lust A., Vermylen J. In vitro and in vivo recovery of cryoprecipitated factor 8. Bibl Haematol. 1970;34:9–17. doi: 10.1159/000384887. [DOI] [PubMed] [Google Scholar]